China's Hisun Pharma To Buy Stake In U.S. PharmTak
This article was originally published in PharmAsia News
Executive Summary
Zhejiang Hisun Pharmaceuticals announced a plan to buy a 24.49 percent stake in U.S. generic drug developer PharmTak Inc., seen as part of Hisun's efforts to expand its presence in the international market and hike its capability in generic drug production